Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1256)
  2. Journal Article (1056)
  3. Review (108)
  4. Editorial (54)
  5. Research Letter (31)
  6. Book Section (22)
  7. Correspondence (20)
  8. Guidelines (11)
  9. Conference Paper (2)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (2465)
  2. Solid Tumor Oncology Division (1880)
  3. Hematologic Malignancies, Division of (1188)
  4. GSK Faculty (1123)
  5. Department of Pathology and Laboratory Medicine (915)
  6. Epidemiology and Biostatistics (861)

More Groups

People
  1. Michael Berger (215)
  2. Marc Ladanyi (191)
  3. Pedram Razavi (184)
  4. Michael Offin (173)
  5. David Solit (166)
  6. Maria Carlo (165)

More People

Years
  1. 2025 (146)
  2. 2024 (370)
  3. 2023 (292)
  4. 2022 (347)
  5. 2021 (307)
  6. 2020 (307)

More Years

Publications
  1. Journal of Clinical Oncology (546)
  2. Blood (248)
  3. Annals of Oncology (98)
  4. Clinical Cancer Research (95)
  5. Journal of Thoracic Oncology (82)
  6. Cancer Research (80)

More Publications

Publishers
  1. American Society of Clinical Oncology (616)
  2. Elsevier Inc. (355)
  3. American Society of Hematology (282)
  4. American Association for Cancer Research (217)
  5. Nature Publishing Group (177)
  6. Oxford University Press (147)

More Publishers

Results (2561)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors
    Meeting Abstract

    Park, W.; Zhang, J.; Dayyani, F.; Shan, J.; Liu, R.; Guo, R.; O'Reilly, E. M.; Liu, Z.; Gao, S.; Wu, X.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Multidimensional analysis of B7 homolog 3 (B7-H3) RNA expression in small-cell lung cancer (SCLC) molecular subtypes
    Meeting Abstract

    Gay, C. M.; Owonikoko, T. K.; Byers, L. A.; Choudhury, N. J.; Ahmed, S.; Cain, Z.; Qian, X. Z.; Brentnall, M.; Heeke, S.; Poi, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma
    Meeting Abstract

    Abou-Alfa, G. K.; Bouattour, M.; Cheng, A. L.; Dayyani, F.; Khalil, D.; Li, D.; Liao, C. Y.; LoĢpez, C. L.; Rimassa, L.; Deutsch, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer
    Meeting Abstract

    Marra, A.; Selenica, P.; Zhu, Y.; Safonov, A.; Razavi, P.; Roulston, A.; Koehler, M.; Curigliano, G.; Ross, D. S.; Weigelt, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • PD-L1 immunohistochemistry in gastric cancer: Comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays
    Meeting Abstract

    Klempner, S. J.; Cowden, E. S.; Cytryn, S. L.; Fassan, M.; Kawakami, H.; Shimada, H.; Tang, L. H.; Wagner, D. C.; Yatabe, Y.; Savchenko, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma
    Meeting Abstract

    Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Shaverdian, N.; Ricciuti, B.; Alessi, J. V. M.; De Giglio, A.; Pecci, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US
    Meeting Abstract

    Razavi, P.; Ahmed, M.; Roush, A.; Parikh, R.; Hitchens, A.; Shen, S.; Safonov, A.; Jhaveri, K. L.; Robson, M. E.; Peacock, N. W.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan
    Meeting Abstract

    Mai, N.; Klar, M.; Ferraro, E.; Bromberg, M.; Chen, Y.; Razavi, P.; Modi, S.; Chandarlapaty, S.; Walsh, E. M.; Drago, J. Z.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma
    Meeting Abstract

    Doshi, S. D.; Dizman, N.; Knezevic, A.; Touma, A.; Alaghehbandan, R.; Ged, Y.; Ornstein, M. C.; Hahn, A. W.; Msaouel, P.; Voss, M. H.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and correlative insights
    Meeting Abstract

    Keane, F.; Tuli, R.; O'Connor, C. A.; Schwartz, C.; Park, W.; Varghese, A. M.; Perry, M.; Singhal, A.; Vardhana, S.; Hendifar, A. E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save